Antibody-mediated remyelination operates through mechanism independent of immunomodulation

Bogoljub Ciric, Virginia Van Keulen, Mateo Paz Soldan, Moses Rodriguez, Larry R. Pease

Research output: Contribution to journalArticlepeer-review

32 Scopus citations


A set of antibodies capable of binding glial cells promotes remyelination in models of multiple sclerosis (MS). Within this set, the mouse antibody, SCH94.03, was immunomodulatory implying that immune system mobilization might be integral to remyelination. We evaluated whether the human remyelination-promoting antibody rHIgM22 influences acquired immunity. The antibody did not bind to immune cells, or influence humoral immune responses, antigen presentation, T cell proliferation or cytokine production. Treatment with rHIgM22 had no effect on demyelination or virus infection in two disease models. These results demonstrate that the remyelination-promoting activity of antibody rHIgM22 is not dependent on immunomodulation.

Original languageEnglish (US)
Pages (from-to)153-161
Number of pages9
JournalJournal of neuroimmunology
Issue number1-2
StatePublished - Jan 2004


  • EAE
  • IgM
  • Immunomodulation
  • Multiple sclerosis
  • Remyelination

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Antibody-mediated remyelination operates through mechanism independent of immunomodulation'. Together they form a unique fingerprint.

Cite this